ロード中...
Ospemifene for the treatment of dyspareunia associated with vulvar and vaginal atrophy: potential benefits in bone and breast
Ospemifene is a selective estrogen receptor modulator (SERM), or estrogen receptor agonist/antagonist, that was recently approved by the US Food and Drug Administration for the treatment of dyspareunia associated with vulvar and vaginal atrophy, a chronic condition that affects up to 60% of postmeno...
保存先:
| 主要な著者: | , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Dove Medical Press
2013
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3792833/ https://ncbi.nlm.nih.gov/pubmed/24109197 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/IJWH.S39146 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|